Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VXRT 
Vaxart Inc (VXRT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: VXRT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Year Target Price $4.67
Year Target Price $4.67
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -76.88% | Avg. Invested days 26 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 103.16M USD | Price to earnings Ratio - | 1Y Target Price 4.67 |
Price to earnings Ratio - | 1Y Target Price 4.67 | ||
Volume (30-day avg) 2 | Beta 1.15 | 52 Weeks Range 0.28 - 1.07 | Updated Date 06/30/2025 |
52 Weeks Range 0.28 - 1.07 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -122.63% | Operating Margin (TTM) -71.54% |
Management Effectiveness
Return on Assets (TTM) -28.9% | Return on Equity (TTM) -114.74% |
Valuation
Trailing PE - | Forward PE 42.73 | Enterprise Value 87745250 | Price to Sales(TTM) 2.18 |
Enterprise Value 87745250 | Price to Sales(TTM) 2.18 | ||
Enterprise Value to Revenue 1.85 | Enterprise Value to EBITDA -0.17 | Shares Outstanding 228223008 | Shares Floating 226926647 |
Shares Outstanding 228223008 | Shares Floating 226926647 | ||
Percent Insiders 1.06 | Percent Institutions 12.08 |
Analyst Ratings
Rating 2 | Target Price 4.67 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Vaxart Inc
Company Overview
History and Background
Vaxart, Inc. was founded in 2004. It's a clinical-stage biotechnology company focused on developing oral recombinant vaccines based on its VectorAdjuvanted Platform Technology. Its initial focus was on influenza and norovirus vaccines but has expanded to include COVID-19 and other diseases.
Core Business Areas
- Oral Vaccine Development: Focuses on creating and testing oral vaccines using its proprietary platform technology. Its primary product is its oral COVID-19 vaccine candidate.
Leadership and Structure
Andrei Floroiu serves as the CEO. The company operates with a typical structure for a clinical-stage biotech company, with departments focusing on research and development, clinical trials, and manufacturing.
Top Products and Market Share
Key Offerings
- Oral COVID-19 Vaccine Candidate: Vaxart's lead product candidate is an oral COVID-19 vaccine. It is currently in clinical trials. Given it is not approved, it has no current market share. Competitors include Pfizer (PFE), Moderna (MRNA), and Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The vaccine market is large and growing, driven by infectious diseases and preventative healthcare. Oral vaccines are a niche within this market.
Positioning
Vaxart is positioned as an innovator in oral vaccine technology. Its competitive advantage lies in the ease of administration and potential for improved immune response compared to traditional injectable vaccines.
Total Addressable Market (TAM)
The global vaccine market is estimated to be hundreds of billions of dollars. Vaxart's TAM is related to the infectious disease segments where oral vaccines can replace injected vaccines.
Upturn SWOT Analysis
Strengths
- Proprietary oral vaccine platform
- Potential for needle-free administration
- Potential for mucosal immunity
- Stable at room temperature (storage advantage)
Weaknesses
- Clinical-stage company with no approved products
- Limited financial resources compared to larger competitors
- Reliance on successful clinical trial outcomes
- Manufacturing scalability risks
Opportunities
- Partnerships with larger pharmaceutical companies
- Expanding vaccine pipeline to address additional diseases
- Securing government funding for vaccine development
- Gaining regulatory approval for its COVID-19 vaccine
Threats
- Failure to achieve positive clinical trial results
- Competition from established vaccine manufacturers
- Regulatory hurdles
- Changes in the vaccine market landscape
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- JNJ
- NVAX
Competitive Landscape
Vaxart's advantage is its oral vaccine technology. Its disadvantage is its size and lack of approved products compared to established competitors.
Growth Trajectory and Initiatives
Historical Growth: Vaxart's historical growth is characterized by fluctuating stock prices based on news related to clinical trial progress and funding announcements.
Future Projections: Future growth depends on the successful development and commercialization of its vaccine candidates. Analyst estimates can vary widely based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing its COVID-19 vaccine clinical trials and expanding its pipeline with new vaccine candidates.
Summary
Vaxart is a high-risk, high-reward clinical-stage biotech company with an innovative oral vaccine platform. While the technology shows promise, the company's future hinges on the success of its clinical trials. The company should prioritize securing funding and partnerships to navigate a very competitive market dominated by pharma giants.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Vaxart's website
- SEC filings
- Analyst reports
- Clinical trial data
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Data is based on available information and subject to change. Investing in clinical-stage biotech companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vaxart Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2018-02-12 | President, CEO & Director Mr. Steven Lo | ||
Sector Healthcare | Industry Biotechnology | Full time employees 105 | Website https://vaxart.com |
Full time employees 105 | Website https://vaxart.com | ||
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.